Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug;35 Suppl 1(Suppl 1):S27-34.
doi: 10.1016/j.nucmedbio.2008.04.007.

A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors

Ioannis Ilias  1 , Karel Pacak
Affiliations
Review

A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors

Ioannis Ilias et al. Nucl Med Biol. 2008 Aug.

Abstract

Pheochromocytomas/paragangliomas are rare tumors; most are sporadic. Biochemical proof of disease is better with measurement of plasma metanephrines and less cumbersome than determinations in urine; its implementation is expanding. Anatomical imaging with computed tomography or magnetic resonance imaging should be followed by functional (nuclear medicine) imaging: chromaffin tumor-specific methods are preferred. Treatment is surgical; for nonoperable disease other options are available. Overall 5-year survival is 50%. Carcinoid tumors derive from serotonin-producing enterochromaffin cells in the fore-, mid- or hindgut. Biochemical screening (and follow-up) is done with measurements of 5-hydroxyindoloacetic acid in urine. For most carcinoids, functional imaging is better than other modalities in localizing primary tumors. Surgery is the treatment of choice; nonresectable tumors are treated with somatostatin analogs or chemotherapy. Overall 5-year survival for patients with carcinoids is 67%.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biosynthetic pathways in pheochromocytomas/paragangliomas and carcinoids; c1: tryptophan hydroxylase; c2: hydroxytryptophan decarboxylase; p1: tyrosine hydroxylase; p2: DOPA decarboxylase; p3: dopamine-beta-hydroxylase; p4: phenylethanolamine-N-methyltransferase
See this image and copyright information in PMC

References

    1. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. Washington, DC: Armed Forces Institute of pathology; 1997. Developmental, physiologic and anatomic aspects of adrenal cortex and medulla; pp. 1–31.
    1. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. Washington, DC: Armed Forces Institute of Pathology; 1997. Adrenal cortical nodules and tumor-like lesions; pp. 49–89.
    1. Young WF., Jr Paragangliomas: clinical overview. Ann N Y Acad Sci. 2006;1073:21–9. - PubMed
    1. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. Washington, DC: Armed Forces Institute of Pathology; 1997. Pheochromocytoma; pp. 223–59.
    1. Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007;21:509–25. - PubMed

Publication types